分期开窗分支腔内主动脉修复期间间隔期主动脉事件的发生率与危险因素
单中心回顾性研究纳入2013至2021年计划分期开窗分支腔内主动脉修复的120例患者,间隔期主动脉事件发生率为13%(16/120),事件组动脉瘤直径显著大于无事件组(76.6 vs 66.5 mm,P ≤ .001),间隔期事件死亡率为69%(11/16),无事件完成修复者无围术期死亡。
要点
- 计划分期开窗分支腔内主动脉修复患者间隔期主动脉事件发生率为13%(16/120)。
- 间隔期主动脉事件患者动脉瘤直径显著大于无事件患者(76.6 vs 66.5 mm,P ≤ .001)。
- 间隔期主动脉事件死亡率为69%(11/16),无事件完成修复者无围术期死亡。
核心结论
- 计划分期开窗分支腔内主动脉修复患者间隔期主动脉事件发生率为13%,包括破裂,规划修复时须与脊髓缺血和近端锚定区优化相平衡。
- 较大动脉瘤,尤其经体表面积校正后,与间隔期主动脉事件相关。
- 对于脊髓缺血风险合理的大于7 cm复杂主动脉瘤患者,规划修复时可考虑缩短分期间隔时间而非单期修复。
研究设计与样本
- 单中心回顾性研究,纳入2013至2021年计划分期开窗分支腔内主动脉修复的患者。
- 591例计划开窗分支腔内主动脉修复患者中142例行第一-stage修复,排除22例无计划第二-stage者,最终120例(平均年龄73 ± 6岁,51%女性)纳入分析。
主要发现
- 间隔期主动脉事件发生率为13%(16/120),包括确诊破裂6例、可能破裂4例、有症状表现4例、早期不明原因间隔期死亡且可能破裂2例。
- 间隔期主动脉事件中位时间为17天(范围2-101天),无并发症完成修复中位时间为82天(四分位距30-147天)。
- 间隔期主动脉事件患者动脉瘤直径显著大于无事件患者(76.6 vs 66.5 mm,P ≤ .001),体表面积校正后差异持续(主动脉尺寸指数3.9 vs 3.5 cm/m2,P = .04),身高校正后亦持续(主动脉高度指数4.5 vs 3.9 cm/m,P ≤ .001)。
- 间隔期主动脉事件死亡率为69%(11/16),无并发症完成修复者无围术期死亡。
- 两组年龄、性别、合并症、家族性主动脉疾病、遗传触发动脉瘤、动脉瘤范围及慢性夹层存在情况相似。
临床怎么用
- 作者认为,对于脊髓缺血风险合理的大于7 cm复杂主动脉瘤患者,规划修复时可考虑缩短分期间隔时间而非单期修复。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Staged endovascular repair of complex aortic aneurysms with first-stage thoracic endovascular aortic repair may decrease the risk of spinal cord ischemia (SCI) associated with fenestrated-branched endovascular aortic repair (FB-EVAR) of thoracoabdominal aortic aneurysms or optimize the proximal landing zone in the cases requiring total aortic arch repair. However, a limitation of multistaged procedures is the risk of interval aortic events (IAEs) including mortality from a ruptured aneurysm. We aim to identify the incidence of and risk factors associated with IAEs during staged FB-EVAR. METHODS: This was a single-center, retrospective review of patients who underwent planned staged FB-EVAR from 2013 to 2021. Clinical and procedural details were reviewed. End points were the incidence of and risk factors associated with IAEs (defined as rupture, symptoms, and unexplained death) and outcomes in patients with or without IAEs. RESULTS: Of 591 planned FB-EVAR patients, 142 underwent first-stage repairs. Twenty-two did not have a planned second stage because of frailty, preference, severe comorbidities, or complications after the first stage and were excluded. The remaining 120 patients (mean age: 73 ± 6 years, 51% female) were planned for second-stage completion FB-EVAR and comprised our cohort. The incidence of IAEs was 13% (16 of 120). This included confirmed rupture in 6 patients, possible rupture in 4, symptomatic presentation in 4, and early unexplained interval death with possible rupture in 2. The median time to IAEs was 17 days (range: 2-101 days), and the median time to uncomplicated completion repairs was 82 days (interquartile range: 30-147 days). Age, sex, and comorbidities were similar between the groups. There were no differences in familial aortic disease, genetically triggered aneurysms, aneurysm extent, or presence of chronic dissection. Patients with IAEs had significantly larger aneurysm diameters than those without IAEs (76.6 vs 66.5 mm, P ≤ .001). This difference persisted with indexing for body surface area (aortic size index: 3.9 vs 3.5 cm/m2, P = .04) and height (aortic height index: 4.5 vs 3.9 cm/m, P ≤ .001). IAE mortality was 69% (11 of 16) compared with no perioperative deaths for those with uncomplicated completion repairs. CONCLUSIONS: The incidence of IAEs was 13% in patients planned for staged FB-EVAR. This represented a notable morbidity, including rupture, which must be balanced with SCI and landing zone optimization when planning repair. Larger aneurysms, especially when adjusted for body surface area, are associated with IAEs. Minimizing time between stages vs single-stage repairs for larger (>7 cm) complex aortic aneurysms in patients with reasonable SCI risk should be considered when planning repair.
引用
- Cirillo-Penn NC, Mendes BC, Tenorio ER, et al. Incidence and risk factors for interval aortic events during staged fenestrated-branched endovascular aortic repair. J Vasc Surg. 2023. PMID: 37290733. doi:10.1016/j.jvs.2023.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。